Weiss Multi-Strategy Advisers’s BioMarin Pharmaceuticals BMRN Stock Holding History

Weiss Multi-Strategy Advisers’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-35,955	Closed	-$3.47M	–	63
2023 Q4	$3.47M	Buy	35,955 +6,330	+21%	+$560K	0.08%	292
2023 Q3	$2.62M	Sell	29,625 -2,621	-8%	-$233K	0.06%	340
2023 Q2	$2.79M	Sell	32,246 -6,226	-16%	-$586K	0.06%	410
2023 Q1	$3.74M	Buy	38,472 +14,064	+58%	+$1.46M	0.09%	317
2022 Q4	$2.53M	Sell	24,408 -9,853	-29%	-$925K	0.07%	351
2022 Q3	$2.9M	Buy	34,261 +21,016	+159%	+$1.87M	0.08%	331
2022 Q2	$1.1M	Sell	13,245 -698	-5%	-$55.6K	0.03%	469
2022 Q1	$1.07M	Sell	13,943 -5,456	-28%	-$457K	0.02%	492
2021 Q4	$1.71M	Sell	19,399 -81	-0.4%	-$6.68K	0.04%	410
2021 Q3	$1.51M	Buy	19,480 +425	+2%	+$33.5K	0.03%	453
2021 Q2	$1.59M	Buy	19,055 +679	+4%	+$53.8K	0.04%	438
2021 Q1	$1.39M	Sell	18,376 -751	-4%	-$61.3K	0.03%	451
2020 Q4	$1.68M	Sell	19,127 -940	-5%	-$74.5K	0.03%	439
2020 Q3	$1.53M	Sell	20,067 -10,004	-33%	-$1.01M	0.04%	377
2020 Q2	$3.71M	Sell	30,071 -4,454	-13%	-$443K	0.11%	246
2020 Q1	$2.92M	Sell	34,525 -1,475	-4%	-$127K	0.11%	219
2019 Q4	$3.04M	Buy	36,000 +1,000	+3%	+$75.5K	0.05%	379
2019 Q3	$2.36M	Hold	35,000	–	–	0.05%	357
2019 Q2	$3M	Buy	35,000 +2,500	+8%	+$214K	0.08%	246
2019 Q1	$2.89M	Sell	32,500 -17,500	-35%	-$1.62M	0.07%	285
2018 Q4	$4.26M	Sell	50,000 -20,431	-29%	-$1.94M	0.18%	140
2018 Q3	$6.83M	Sell	70,431 -9,569	-12%	-$955K	0.18%	143
2018 Q2	$7.54M	Sell	80,000 -10,000	-11%	-$876K	0.18%	155
2018 Q1	$7.3M	Buy	90,000 +10,000	+13%	+$858K	0.23%	122
2017 Q4	$7.13M	Buy	80,000 +10,000	+14%	+$870K	0.18%	137
2017 Q3	$6.51M	Buy	70,000 +26,500	+61%	+$2.34M	0.24%	113
2017 Q2	$3.95M	Sell	43,500 -1,500	-3%	-$136K	0.17%	183
2017 Q1	$3.95M	Buy	45,000 +20,000	+80%	+$1.78M	0.16%	178
2016 Q4	$2.07M	Buy	25,000 +5,000	+25%	+$430K	0.1%	197
2016 Q3	$1.85M	Buy	20,000 +5,420	+37%	+$510K	0.11%	229
2016 Q2	$1.13M	Sell	14,580 -10,420	-42%	-$886K	0.09%	254
2016 Q1	$2.06M	Buy	25,000 +5,000	+25%	+$407K	0.09%	256
2015 Q4	$2.1M	Sell	20,000 -40,000	-67%	-$4.18M	0.14%	170
2015 Q3	$6.32M	Sell	60,000 -6,000	-9%	-$801K	0.28%	76
2015 Q2	$9.03M	Buy	66,000 +1,000	+2%	+$124K	0.36%	80
2015 Q1	$8.1M	Buy	65,000 +20,000	+44%	+$2.12M	0.36%	77
2014 Q4	$4.07M	Buy	45,000 +10,000	+29%	+$832K	0.14%	142
2014 Q3	$2.53M	Sell	35,000 -1,060	-3%	-$69.7K	0.06%	278
2014 Q2	$2.24M	Buy	36,060 +360	+1%	+$21.7K	0.05%	321
2014 Q1	$2.44M	Sell	35,700 -25,130	-41%	-$1.85M	0.05%	317
2013 Q4	$4.28M	Sell	60,830 -9,170	-13%	-$623K	0.09%	257
2013 Q3	$5.05M	Buy	70,000 +20,000	+40%	+$1.33M	0.11%	222
2013 Q2	$2.79M	Buy	+50,000	New	+$3.12M	0.08%	291

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Weiss Multi-Strategy Advisers's BMRN Position: Q1 2024 in Review

Weiss Multi-Strategy Advisers sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2024, closing a stake of 35,955 shares — an estimated $3.47M sold.

Weiss Multi-Strategy Advisers first reported a position in BMRN in Q2 2013 and held it in 43 quarters. The position peaked at $9.03M in Q2 2015. 560 funds tracked by Wall St. Rank hold BMRN as of Q1 2024.

Weiss Multi-Strategy Advisers reported no remaining BioMarin Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Weiss Multi-Strategy Advisers sold 35,955 BioMarin Pharmaceuticals shares in Q1 2024, an estimated $3.47M.
Weiss Multi-Strategy Advisers first reported a position in BioMarin Pharmaceuticals in Q2 2013 and held it in 43 quarters.
Weiss Multi-Strategy Advisers's BioMarin Pharmaceuticals position peaked at $9.03M in Q2 2015.
560 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2024.

Based on Weiss Multi-Strategy Advisers's 13F filing for Q1 2024.